This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, Biosimilars & Biotech. Check out our full report below:

AbbVie and Genmab Highlight P-I/II (EPCORE NHL-2) Study Data of Epcoritamab to Treat R/R Follicular Lymphoma (FL) at ASH 2024

Read More: AbbVie and Genmab

Merck Highlights the P-II (WaveLINE-007) Study Data of Zilovertamab Vedotin to Treat Diffuse Large B-Cell Lymphoma at ASH 2024

Read More: Merck

AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH 2024

Read More: AstraZeneca

Roche Highlights 5-year Analysis from P-III (POLARIX) Study of Polivy (Polatuzumab Vedotin) for Diffuse Large B-Cell Lymphoma (DLBCL) at ASH 2024

Read More: Roche

AbbVie Reports Results from the P-III (TEMPO-2) Study of Tavapadon for Parkinson's Disease

Read More: AbbVie

Merck Reports the P-III (KEYLYNK-001) Study Data of Keytruda for Treating Advanced Epithelial Ovarian Cancer

Read More: Merck

Eli Lilly to Highlight P-III (BRUIN CLL-321) Trial Data of Jaypirca (Pirtobrutinib) for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at ASH 2024

Read More: Eli Lilly

Incyte Highlights the P-III (inMIND) Study Data of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024

Read More: Incyte

Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

Read More: Novartis

Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (AML)

Read More: Daiichi Sankyo

Dizal Reports Pooled Analysis from the Trials of Sunvozertinib to Treat Non-Small Cell Lung Cancer

Read More: Dizal

Eli Lilly Reports the P-III (EMBER-3) Trial Results of Imlunestrant to Treat ER+/HER2- Advanced Breast Cancer

Read More: Eli Lilly

AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer

Read More: AstraZeneca and Merck

Repare Therapeutics Reports the P-I (MYTHIC) Trial Data of Lunresertib Plus Camonsertib to Treat Gynecologic Cancers

Read More: Repare Therapeutics

GSK Reports the US FDA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

Read More: GSK

Seres Therapeutics’ SER-155 Secures the US FDA’s Breakthrough Therapy Designation to Reduce Bloodstream Infections

Read More: Seres Therapeutics

HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer

Read More: HUTCHMED

SpliceBio Receives the US FDA IND Clearance to Initiate P-I/II Trial of SB-007 for Treating Stargardt Disease

Read More: SpliceBio

Sobi Reports the US FDA’s sNDA Acceptance of Doptelet (Avatrombopag) to Treat Pediatric Immune Thrombocytopenia

Read More: Sobi

Roche Reports the EMA’s Approval of Vabysmo Prefilled Syringe (PFS) for three Retinal Conditions Causing Blindness

Read More: Roche

Ascendis Pharma Reports the US FDA’s sBLA Acceptance of TransCon hGH for Treating Growth Hormone Deficiency

Read More: Ascendis Pharma

Relation Partners with GSK to Develop Therapies Targeting Fibrotic Diseases and Osteoarthritis

Read More: Relation and GSK

BeiGene and CSPC Pharmaceutical Collaborate to Develop SYH2039 for Solid Tumors

Read More: BeiGene and CSPC Pharmaceutical

HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe

Read More: HUTCHMED

AngioDynamics’ NanoKnife System Secures the US FDA’s 510(k) Clearance for Prostate Tissue Ablation

Read More: AngioDynamics

SetPoint Medical Reports PMA Submission of SetPoint System to the US FDA for Treating Rheumatoid Arthritis

Read More: SetPoint Medical

Microbot Medical Reports Regulatory Submission for LIBERTY Endovascular Robotic System to the US FDA

Read More: Microbot Medical

RapidPulse Secures the US FDA’s Approval to Initiate IDE Study of Cyclic Aspiration System in Patients with Acute Ischemic Stroke

Read More: RapidPulse

Celltrion’s Omlyclo (CT-P39) Secures the Health Canada’s Approval (Biosimilar, Xolair)

Read More: Celltrion

KIND Pharmaceutical Reports Preclinical Results of AND017 in Animal Models of Multiple Disorders

Read More: KIND Pharmaceutical

Related Post: PharmaShots Weekly Snapshots (December 02 – December 06, 2024)